Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zandelisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
    MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan

    07 Dec 2022

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/mei-kyowa-kirin-zandelisib/

    PHARMACEUTICAL-TECHNOLOGY
    07 Dec 2022
    Share Share
    MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
    MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan

    06 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221205005800/en/MEI-Pharma-and-Kyowa-Kirin-Announce-Discontinuation-of-Zandelisib-Development-Outside-of-Japan-Following-Recent-FDA-Meeting

    BUSINESSWIRE
    06 Dec 2022
    Share Share
    MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220801005185/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology
    MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology

    18 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220718005236/en

    BUSINESSWIRE
    18 Jul 2022
    Share Share
    MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022
    MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022

    04 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220604005001/en

    BUSINESSWIRE
    04 Jun 2022
    Share Share
    FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny
    FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny

    26 Mar 2022

    // Jonathan Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/mei-kyowa-kirin-zandelisib-FDA-new-trial-accelerated-approval/621042/

    Jonathan Gardner BIOPHARMADIVE
    26 Mar 2022
    Share Share